DAN-311 / Dantari - LARVOL DELTA

Dantari Debuts with $47 Million Series A to Advance Best-in-Class Targeted Medicines for Solid Tumors (PRNewswire) - "Dantari, Inc...announced its emergence from stealth mode with $47 million Series A financing....Dantari's pipeline also includes several next-generation ADC programs leveraging the T-HDC platform. The Company's next program, DAN-311 for HER2-positive and HER2-low breast cancer, is planned to enter the clinic in the second half of 2023. Dantari's other T-HDC product candidates combining validated targets and payloads for a variety of solid tumors including prostate cancer are progressing through preclinical development."

Financing • New trial • Pipeline update • Breast Cancer • Genito-urinary Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Prostate Cancer • Solid Tumor